Investor-pleasing news from the FDA regarding Dublin-based Avadel Pharmaceuticals plc's pivotal phase III trial testing once-nightly sodium oxybate (FT-218) for narcolepsy sparked Wall Street speculation regarding what the update might mean for Jazz Pharmaceuticals plc, also of Dublin, which markets twice-nightly Xyrem (sodium oxybate) in the space.